Purpose

To determine rate and severity of chemotherapy induced neuropathy in extremities treated with cold gloves and socks versus control extremities

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Histologically confirmed diagnosis of early stage breast cancer (stage I-III). - Planned to receive treatment with either adjuvant or neo-adjuvant taxane-based chemotherapy. - Age > 18 years. There is no upper age limit for participation in this study. - Patients may have received any of the following therapies: surgery, chemotherapy, hormones, biologics, or radiation. - Prior chemotherapies are permitted, except with prior treatments with taxanes, vinca alcaloids, gemcitabine, eribulin, ixabepilone, platinum drugs) - All patients will have given signed, informed consent prior to registration - Patients must have a performance status of ECOG 0 or 1.

Exclusion Criteria

  • Patients must not have received any prior taxane or platinum based chemotherapy. - Patients must not have a history of peripheral neuropathy (regardless of cause). - Patient must not have a history of Raynaud's disease. - Patients with partial or complete limb amputations. - Known hypersensitivity to cold - Patient cannot be on the following medications: GABA analogues (such as Neurontin, lyrica), tricyclic antidepressants (such as amitriptyline or nortriptyline) - As judged by the investigator, severe uncontrolled concurrent medical conditions, psychiatric illness or social condition that would limit compliance with study requirements. - Evidence of any significant clinical disorder or laboratory finding that makes it undesirable for the subject to participant in the clinical trial - Must not be pregnant or breast feeding

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Cryotherapy
Each patient will receive cryotherapy administered during each neurotoxic chemotherapy agent infused treatments by Elasto gel™ Hypothermia gloves and socks. Patients will wear the glove and sock for 15 minutes prior to treatment start and 15 minutes following treatment completion, for a total of 30 minutes.
  • Device: Cryotherapy
    An Elasto gel™ frozen (4°C) glove and sock
    Other names:
    • Cold therapy
    • Elasto gel™

More Details

Status
Active, not recruiting
Sponsor
The University of Texas Health Science Center at San Antonio

Study Contact

Detailed Description

This is a therapeutic study investigating the use of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy (CIPN) and associated nail toxicities. The therapeutic intervention will involve patients wearing an Elasto-Gel cold glove and sock on one hand and one foot (both on the right side or both on the left side). The patients will wear the glove and sock during each infusion of taxane chemotherapy.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.